
Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
GHRH analogue
Tesamorlin
In stock
A synthetic GHRH analogue used in controlled receptor, peptide-stability, and development research.
Order within — · ships today Cutoff 10:00 · local time
Arrives Sep 21 - Sep 23 to Europe
Tesamorlin
Price range: 92,90 € through 161,00 €
Trans-3-hexenoyl GHRH analogue for receptor and endocrine marker studies.
Scroll horizontally to reach every product-information tab.
Research overview
Tesamorlin
Tesa is the current catalogue name for tesamorelin, a synthetic analogue of growth-hormone-releasing hormone. Its engineered peptide design is studied in relation to the GHRH-receptor family and distinguishes it from the unmodified parent sequence and shorter GHRH fragments.
The authoritative records establish tesamorelin identity, while the cited primary report documents the compound within a controlled clinical research programme. That literature supplies development and receptor-family context without defining a use or expected result for this product; the selected lot's identity and measured content remain governed by its exact product record and signed analytical certificate.
Compound information
Specifications
Molecular profile
- Sequence
- trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- Molecular mass
- 5135.9 g/mol
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- GHRH analogue research compound; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Latest test results
Documentation is available on request
Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.
Your batch is confirmed when your order is allocated.Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg
> 99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 9.44 mg
- PurityPeptide screening
- > 99.8%
- Identity (FTIR)FTIR spectrum
- 997
- Identity (RT)Retention time
- 0.999
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- < 0.001 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: Tesamorelin
Authoritative identity record for the compound sold under the Tesa catalogue name.
PubChem · View source ↗Chemical Abstracts Service
CAS Common Chemistry: 218949-48-5
Authoritative CAS Registry Number record for Tesamorelin.
CAS Common Chemistry · View source ↗Russo SC, Ockene MW, Arpante AK, et al. · 2024
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Primary clinical research report for the compound described as Tesamorelin.
AIDS · 10.1097/qad.0000000000003965 View source ↗Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
The Journal of clinical endocrinology and metabolism · View source ↗Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK · 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
The lancet. HIV · View source ↗Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV · 2012
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Archives of neurology · View source ↗Lauritzen L, Amundsen ID, Damsgaard CT, Lind MV, Schnurr TM, Hansen T, Michaelsen KF, Vogel U · 2019
FADS and PPARG2 Single Nucleotide Polymorphisms are Associated with Plasma Lipids in 9-Mo-Old Infants
The Journal of nutrition · View source ↗Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK · 2020



